Furthermore, current clinical practices, including notable outcomes associated with HF medications, such as the “fantastic four” strategy and SGLT2 inhibitors for HFpEF, may differ from those observed in cases predating the adoption of DOACs and these specific therapeutic interventions. Here, SLC5A2 is linked to hydrops fetalis.